Rhumbline Advisers Unity Biotechnology, Inc. Transaction History

Rhumbline Advisers

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$4.15 - $6.3 $155,056 - $235,386	-37,363 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$5.51 - $9.42 $8,540 - $14,601	-1,550 Reduced 3.98%	37,363 $224,000
Q4 2020 Feb 10, 2021	BUY	$3.42 - $6.36 $8,892 - $16,536	2,600 Added 7.16%	38,913 $204,000
Q3 2020 Nov 12, 2020	SELL	$2.94 - $12.43 $13,212 - $55,860	-4,494 Reduced 11.01%	36,313 $126,000
Q2 2020 Aug 13, 2020	BUY	$5.28 - $9.67 $21,980 - $40,256	4,163 Added 11.36%	40,807 $354,000
Q1 2020 May 06, 2020	BUY	$5.0 - $7.6 $500 - $760	100 Added 0.27%	36,644 $213,000
Q4 2019 Feb 05, 2020	BUY	$5.99 - $8.38 $2,653 - $3,712	443 Added 1.23%	36,544 $263,000
Q3 2019 Oct 23, 2019	BUY	$5.62 - $9.63 $5,204 - $8,917	926 Added 2.63%	36,101 $220,000
Q2 2019 Aug 14, 2019	BUY	$7.59 - $10.21 $30,230 - $40,666	3,983 Added 12.77%	35,175 $334,000
Q1 2019 May 01, 2019	BUY	$7.65 - $16.66 $6,273 - $13,661	820 Added 2.7%	31,192 $253,000
Q4 2018 Jan 31, 2019	BUY	$10.76 - $17.25 $326,802 - $523,917	30,372 New	30,372 $494,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $16.1M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.